Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

NCT07732413 is registered in ClinicalTrials.gov with Lumos Pharma as lead sponsor.

NCT NCT07732413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07732413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer
Lead sponsor
Lumos Pharma
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 8, 2026
Completion date
October 8, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

progressive pediatric brain cancer